We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Tampilkan postingan dengan label promise. Tampilkan semua postingan
Tampilkan postingan dengan label promise. Tampilkan semua postingan

Sabtu, 01 Oktober 2011

Pinky promise may save young dad's life

AppId is over the quota
AppId is over the quota
"I'm going all the way with [Autumn] by my side and our pinky fingers held high in the air," Justin Boyles said.Justin Boyles learned he had type 2 diabetes in March 2011Since making a promise to his daughter, Boyles has lost more than 65 poundsBoyles raised $7,500 for the American Diabetes Association's "Step Out: Walk to Stop Diabetes"

Duncan, Oklahoma (CNN) -- Justin Boyles lay in bed, exhausted and depressed. His 385-pound body sank into the mattress with each breath he took. I have diabetes, he thought in disbelief.

His 6-year-old daughter, Autumn, crawled on top of the king-sized comforter and stared at him with bright blue eyes.

"Daddy, will you get up and play?"

"No, baby, I'm tired."

She sat back to think. Her mom had tried to explain why Justin was so sad, but Autumn didn't really understand diabetes or its dangerous implications.

"Daddy, are you ever going to be healthy enough to ride a bike with me?"

The question broke Justin's heart. Tears started to roll down his face. "Yes, very soon. I promise," he said.

"Do you pinky promise?" she asked, holding out her tiny finger.

Justin looped his last digit around hers and made the decision to change his life.

All kinds of excuses

Shanon and Justin Boyles were high school sweethearts. The first time they hung out at 16, Justin took Shanon to church. He was smart, polite and made her laugh -- three qualities that helped Shanon overlook his size.

"As long as I can remember, I've been overweight," Justin says. "I remember as a child coming home after school and having a stack of cookies and a giant glass of milk every day."

In high school Justin weighed close to 250 pounds; he was considered obese even at 6 feet 1. As an adult he lived on fast food and spent most of his nights as a security guard sitting down. He'd eat dinner at work -- frozen burritos, burgers and fries -- then stop off at Taco Bell on the way home for the advertised fourth meal.

Shanon and Autumn Boyles wear their \ Shanon and Autumn Boyles wear their "Do you pinky promise?" shirts at the "Step Out: Walk to Stop Diabetes."

"I was really kind of in my own little hole, and I didn't want to get out or do anything," he says.

Shanon became worried. Any time their extended family tried to get together for a birthday party or holiday, Justin refused to go.

"He would have all kinds of excuses," she says. "He was really depressed. He was down on himself real bad."

Most concerning was his lack of time with Autumn, who got upset when her father wouldn't play outside.

"She loves him. He's her hero," Shanon says. "I [knew] why he was feeling that way... but there was nothing I could do about it."

Small steps for a big change

Since his diagnosis with type 2 diabetes in March -- and his pinky promise to Autumn -- Justin has lost more than 65 pounds. He walks around his neighborhood whenever he can and makes sure to do the little things like taking the stairs and returning his shopping cart. The family is also eating better with more vegetables, leaner meats and less sugar. For example, at dinner Justin usually eats a spinach leaf salad with tuna or baked chicken with broccoli. Shanon joins in; she's lost 20 pounds in less than six months on the new diet.

The family recently took a trip to the Oklahoma State Fair and walked around all day, something they never would have done last year.

"I no longer lay in bed thinking that my weight is just too much to overcome," Justin says. "I enjoy being out with family and friends and having a good time."

He only weighs in once a month to avoid becoming obsessed with the numbers on the scale. He hopes to get down to 200 pounds, a weight at which his doctor said he would probably be able to go off his medications.

"I just want him to be healthy and happy. I don't care what weight he's at," Shanon says.

The couple raised more than $7,500 for the American Diabetes Association's "Step Out: Walk to Stop Diabetes" in Oklahoma City on September 14. Their team wore matching black T-shirts with a new slogan: "Do you pinky promise?"

On his website Justin has included a section where he asks readers to make their own promises -- to themselves or to their family -- to get healthy.

"[Autumn] taught me that you can do anything you put your mind to," he says. "It doesn't take a big giant step.It takes doing a little something."

Justin still has a long way to go in his weight loss journey. But rest assured that he'll keep going -- you just don't break a pinky promise, especially one made to your little girl.

Got a weight loss story to share? Submit it on iReport.com



View the original article here



Peliculas Online

Senin, 26 September 2011

Novartis's Afinitor shows promise in breast cancer

AppId is over the quota
AppId is over the quota
By Kate Kelland

STOCKHOLM | Sun Sep 25, 2011 6:03pm EDT

STOCKHOLM (Reuters) - C ombining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.

Investigators conducting a clinical trial found that women treated with a combination of Novartis' Afinitor or everolimus, and Pfizer's oestrogen-blocker Aromasin, known generically as xemestane, had progression-free survival (PFS) of as much as seven months more than women treated with the Pfizer drug alone.

"This is a highly significant improvement in the time to disease progression. It's quite remarkable," said Jose Baselga of Massachusetts General Hospital and Harvard Medical School, who led the trial and presented the data at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm.

He said side effects were consistent with those previously reported in trials of Afinitor and did not lead to a worse quality of life for patients on the drug.

Baselga's analysis of the data showed that PFS for women in the Afinitor group was 6.9 months versus 2.8 months for those not taking the Novartis drug -- a 57 percent improvement.

The trial was stopped early after a separate independent analysis by a central review committee showed that Afinitor extended PFS to 10.6 months compared to 4.1 months -- a 64 percent improvement.

"These results are impressive and, potentially, could represent a new therapeutic option," Baselga said.

Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism. Novartis says there are around 220,000 newly diagnosed cases worldwide each year of the type of advanced breast cancer that could benefit from Afinitor.

Novartis has been upbeat about the prospects for the drug, which is already approved for other types of cancer, such as kidney and a rare type of pancreatic cancer.

The Swiss firm's CEO Joe Jimenez told Reuters in a recent interview it could generate an extra $1 billion or more in annual sales from its new use in breast cancer. [ID:nL5E7K227N]

Herve Hoppenot, president of Novartis's oncology division, said the magnitude of benefit seen in this trial showed that Afinitor is "a potential important new treatment approach".

The Swiss drugmaker is planning to file for regulatory approval of Afinitor in breast cancer by the end of this year.

Novartis reported Afinitor sales for cancer of $243 million in 2010 but analysts expect that number to balloon if the drug is licensed in breast cancer. Thomson Reuters Pharma data show analysts on average forecast sales of $1.53 billion by 2016.

The hormone oestrogen promotes the growth of about two thirds of breast cancers, and hormonal therapies such as Aromasin which block the effect of oestrogen or reduce its levels are used to treat these so-called hormone receptor-positive breast cancers.

But many breast cancer patients, and nearly all those with advanced forms of the disease where it has spread to other parts of the body, become resistant to hormonal therapy.

"When patients stop responding to hormonal therapy, the benefits from any secondary therapy are limited," Baselga said.

The Phase III clinical trial, known as BOLERO 2, was designed to test the efficacy of Afinitor in patients resistant to aromatase inhibitors - drugs that cut the amount of oestrogen produced and help to slow or reverse the growth of the cancer.

It was as conducted in 24 countries in 724 patients with an average age of 62. All patients had already been treated with the aromatase inhibitors anastrozole, sold by AstraZeneca as Arimidex, or the generic drug letrozole. Some had also been treated with tamoxifen, fulvestrant and chemotherapy.

Pfizer's Aromasin lost its patent in April and is now available in a cheaper generic version.

(Editing by Greg Mahlich)



View the original article here



Peliculas Online

Senin, 19 September 2011

Sangamo gene therapy shows promise in reducing HIV

AppId is over the quota
AppId is over the quota
By Deena Beasley

Sun Sep 18, 2011 1:18pm EDT

n">(Reuters) - An early stage trial of Sangamo BioSciences Inc's HIV treatment found that the gene therapy reduced levels of the virus and even eliminated it in one patient with a naturally occurring gene mutation.

The very small Phase 1 trial tested the SB-728-T gene therapy, which is designed to disrupt the CCR5 gene used by HIV to infect cells of the immune system.

If shown to be safe and effective, the treatment could end the need for the antiretroviral drugs now used to keep the virus that causes AIDS in check by suppressing viral replication in the blood.

Trial results presented in Chicago on Sunday at the Interscience Conference on Antimicrobial Agents and Chemotherapy show a "statistically significant relationship between estimated modification of both copies of the CCR5 gene and viral load," said Dr. Carl June, trial investigator and director of translational research at the University of Pennsylvania's cancer research institute.

In a statement, June said the results suggest the need to increase the frequency of the modified cells in HIV-infected patients, which could lead to a "functional cure" for AIDS, but the means of achieving this have not been clarified.

Sangamo said earlier this year that a single infusion of the treatment improved immune system damage in nearly all of the subjects analyzed in the first trial of the therapy in humans.

The 10 patients in the trial were on antiretroviral therapy when the study began. After four weeks, six of them went on a "treatment interruption," during which they stopped taking antiviral medication for 12 weeks.

Viral load decreased in three of the six subjects, with one patient's viral load reduced to undetectable levels. That patient carried a naturally occurring mutation in one copy of his CCR5 gene.

Humans contain two copies of each gene, one from the father and one from the mother, which sometimes are referred to as the alleles of a gene.

"Since one copy of his gene was already disrupted naturally, twice as many of his cells were 'biallelically' modified," Sangamo Chief Executive Officer Edward Lanphier said in a telephone interview, meaning that both members of the CCR5 gene pair were knocked out.

He estimated that between 5 percent and 10 percent of HIV patients carry the genetic mutation.

Around 33 million people worldwide have the human immunodeficiency virus (HIV) that causes AIDS. Major producers of current HIV drugs include Gilead Sciences and GlaxoSmithKline.

Lanphier said Sangamo will move ahead with a strategy to maximize the number of cells that can be "biallelically" modified by SB-728-T. Options include targeting only the small segment of patients with mutated CCR5 genes or using "strategies that boost the amount of engraftment of modified cells."

The CEO said he plans to unveil details of Sangamo's plans at an investment banking conference in New York on Wednesday.

Lanphier emphasized that the company intends to take the HIV treatment into mid-stage trials without a partner.

"We have more than sufficient cash to push forward into Phase 2 trials," he said, reaffirming that Sangamo expects to have cash holdings of at least $85 million at year-end.

(Reporting by Deena Beasley in Los Angeles)



View the original article here



Peliculas Online